[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-40;  41-60;  61-8081-100101-120121-140; 141-160; 161-180;  181-200201-220221-240241-260261-280; 281+

NICE TAs 181-200

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA181 

Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)

 

EMCN algorithm

DHFT protocol

TA182

Acute coronary syndrome - prasugrel (TA182)

2.9 Antiplatelet drugs

 

TA183

Cervical cancer (recurrent) - topotecan (TA183)

 

EMCN algorithm

DHFT protocol

TA184

Lung cancer (small-cell) - topotecan (TA184)

 

EMCN algorithm

DHFT protocol

TA185

Soft tissue sarcoma - trabectedin (TA185)

 

EMCN algorithm

DHFT protocol

TA186 

Rheumatoid arthritis - certolizumab pegol (TA186)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA187

Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)

1.5 Treatment of chronic diarrhoeas: 1.5.3 Drugs affecting the immune response

 

TA188

Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)  

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

 

TA189

Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189)  

 

EMCN algorithm

DHFT protocol

TA190 

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)

 

EMCN algorithm

DHFT protocol 

TA191

Gastric cancer (advanced) - capecitabine (TA191)

 

EMCN algorithm

DHFT protocol 

TA192

Lung cancer (non-small-cell, first line) - gefitinib (TA192)

 

EMCN algorithm

DHFT protocol 

TA193 

Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)

8.2 Drugs affecting the immune response: 8.2.3 Rituximab & Alemtuzumab

EMCN algorithm

DHFT protocol

TA194

Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194)

Withdrawn

 

TA195

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA196

Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)

 

EMCN algorithm

DHFT protocol 

TA197

Atrial fibrillation - dronedarone (TA197)

2.3 Anti-arrythmic drugs

 

TA198 

Rheumatoid arthritis - tocilizumab (TA198) (replaced by TA247)

Withdrawn 

 

TA199

Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

13.5.3 Drugs affecting the immune response

 

TA200

Hepatitis C - peginterferon alfa and ribavirin (TA200) 

5.3 Antiviral drugs: 5.3.3 Viral Hepatitis